Patients with cancer are at high risk of developing infectious complications, especially during episodes of severe neutropenia (2) . We have recently noted an increase in the incidence of infections caused by Citrobacter spp. in patients with cancer admitted to our hospital. Between 1972 and 1985, the incidence of bacteremias caused by Citrobacter spp. has shown an eightfold increase.
In this study, we evaluated the in vitro activity of 16 antibiotics, including two new quinolones, against isolates of Citrobacter spp. obtained from blood culture specimens of patients treated at our institution between 1977 and 1985. The organisms were identified to species level by the scheme of Kelly et al. (11) .
Susceptibility testing was performed by using a previously described microtiter broth dilution method (10) . Briefly, the organisms were incubated overnight in Mueller-Hinton broth, and appropriate dilutions were made so that the final inoculum was 105 CFU/ml. The The two quinolones tested, which are not currently used at our institution, were also very active against both species. From 1977 to 1985, C. diversus did not acquire resistance to any of the antibiotics tested. On the other hand, whereas only 33% of C. freundii isolates were resistant to cefamandole, ceftriaxone, and ceftazidime in 1980, 100, 63, and 88%, respectively, were resistant in 1985.
Differences in susceptibility between C. freundii and C. diversus, especially for penicillins and cephalosporins, have been reported previously (3, 9, 12) . Both species have been found to be susceptible to aminoglycosides and imipenem and most susceptible to the quinolones (1, 3, 4, 7, 8, 10, 13,  16 ). Of 22 Citrobacter spp. tested at our institution during a previous study, 90% were susceptible to aztreonam (5) . Resistance of C. freundii to aztreonam, ceftazidime, and piperacillin has also been observed by other investigators (1, 4, 6, 15) .
Our study shows that there is a difference in susceptibility to various antibiotics between the two Citrobacter species. Overall, C. diversus was often more susceptible to antibiotics than C. freundii was. C. diversus isolates may show a bimodal distribution, with one subpopulation being extremely susceptible and the other being multidrug resistant. This was not so among our isolates. The most active drugs currently available against Citrobacter spp. are amikacin and imipenem. The unique susceptibilities of Citrobacter spp. need to be recognized in those institutions where these organisms have become frequent pathogens.
